Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland
- 31 March 2020
- journal article
- research article
- Published by Physicians Postgraduate Press, Inc in British Journal of Psychology
- Vol. 81 (3)
- https://doi.org/10.4088/JCP.19m12796
Abstract
Psychiatric patients are susceptible to cardiovascular disease (CVD), but this risk is poorly understood. This study compared CVD risk in psychiatric patients taking weight gain–inducing drugs with that in the general population.Keywords
This publication has 36 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- The Metabolic Syndrome, Oxidative Stress, Environment, and Cardiovascular Disease: The Great ExplorationExperimental Diabetes Research, 2012
- Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-AnalysisSchizophrenia Bulletin, 2011
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?Acta Psychiatrica Scandinavica, 2009
- Predictive accuracy and usefulness of calibration of the ESC SCORE in SwitzerlandEuropean Journal of Preventive Cardiology, 2008
- Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetesSchizophrenia Research, 2008
- The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndromeBMC Cardiovascular Disorders, 2008
- Clinical Impact of Metabolic Syndrome and Its Additive Effect With Smoking on Subsequent Cardiac Events After Acute Myocardial InfarctionThe American Journal of Cardiology, 2007
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEuropean Heart Journal, 2003
- AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 UpdateCirculation, 2002